Current Status of Compounding of Semaglutide: With respect to the current status of compounding of semaglutide, FDA noted that it wished to avoid unnecessary disruption to patient treatment, and outlined the current enforcement policy moving forward: [T]he agency does not intend to take action against compounders for violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act) arising from conditions that depend on semaglutide injection products inclusion on FDAs drug shortage list: For a state-licensed pharmacy under section 503A of the FD&C Act compounding, distributing or dispensing semaglutide injections within 60 calendar days from todays announcement, until
doi: 10.1093/gerona/63.4.414 68
This prevents muscle loss and nutritional deficiency during weight loss
34 : (Suppl 1) 281281 Pettegrew JW, Moossy J, Withers G, McKeag D, Panchalingam K
Thats why we use body composition scans in our Bend and Seattle clinics
Additionally, interim findings from the ongoing phase 3 ESSENCE trial suggest that semaglutide 2.4 mg may have a disease-modifying role in metabolic dysfunction-associated steatohepatitis (MASH)